Global tel link 800 number

CGG Announces its 2018 Third Quarter Results Q3 2018: strong Equipment growth IFRS figures1: revenue at $439m, OPINC at $45m, net income at $(2)m Segment revenue2 at $333m, up 4% year-on-year Segment EBITDAs2 at $109m, up 22% year-on-year, a 33% margin Segment operating income2 at $40m, versus $(24)m last year, a 12% margin /EIN News/ -- Q3 operational highlights Geoscience (SIR): robust demand for advanced imaging dedicated to reservoir delineation and production Multi-Client: high level of after-sales in active basins but lower prefunding with c. $25m delayed to October Equipment: demand for land picking up strongly in Middle East and Asia Contractual Data Acquisition: solid fleet availability rate at 93% in continued difficult market Sound financial situation Good cash management with segment FCF at $(17)m Net debt of $769m at end of September, liquidity of $412m and leverage ratio at 1.9x   1 Based on transitory … [Read more...] about CGG : CGG Announces its 2018 Third Quarter Results

Initiated a Phase 2 trial of RPL554 as add-on to dual bronchodilator therapy for COPD maintenance treatment; enrolled last patient and dosing underway Progressed DPI and pMDI programs; formulations for clinical development now selected LONDON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today an operational update and financial results for the three months and nine months ended September 30, 2018. The Company’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (“PDE3 and PDE4”), that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease … [Read more...] about Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018

IRVINE, CA, Sept. 28, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the Company has appointed Dr. Joe Wilson, an information technology (IT) and risk management expert, to its International Government Affairs Board (IGAB). For over 20 years, Dr. Wilson has successfully promoted the adoption and use of IT security standards and measurements inside public and private organizations. He has been an active participant with the development of the National Institute of Standards and Technology (NIST) Cybersecurity Framework, and will advise CBIS in a number of areas, including IT security, risk management, blockchain applications, international collaborations, and public/private partnerships. As a military veteran, Dr. Wilson provides volunteer services to the American Red Cross to assist veterans’ with transitioning into cybersecurity work … [Read more...] about Cannabis Science, Inc. Appoints Dr. Joe Wilson, an Information Technology and Risk Management Expert, to Its International Government Affairs Board